title: [Immunomodulator Cycloferon in the comprehensive treatment of patients with acute non-lymphoblastic leukemia].
abstract: The therapeutic benefit and action of the immunomodulator Cycloferon were evaluated in patients with acute non-lymphoblastic leukemia. When administered in conjunction with chemotherapy during first complete remission, it reduced both early-onset relapse frequency and degree of cytostatic-induced immune deficiency. The drug's action is mediated by changes taking place in cytokine and interferon synthesis.
authors.affiliation: Russian Research Institute of Hematology and Transfusiology, St. Petersburg.
authors.forename: S I
authors.initials: SI
authors.lastname: Moiseev
authors.forename: K M
authors.initials: KM
authors.lastname: Abdulkadyrov
authors.forename: L N
authors.initials: LN
authors.lastname: Bubnova
authors.forename: T V
authors.initials: TV
authors.lastname: Glazanova
authors.forename: O E
authors.initials: OE
authors.lastname: Rozanova
authors.forename: I E
authors.initials: IE
authors.lastname: Pavlova
authors.forename: V A
authors.initials: VA
authors.lastname: Balashova
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
mesh_terms: D000166:Acridines / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000166:Acridines; D000276:Adjuvants, Immunologic; D007369:Interferon Inducers; C026430:10-carboxymethyl-9-acridanone